Genetypes

GeneType Predicting Risk of Pancreatic Cancer: Major Breakthrough in Early Detection and Treatment

Retrieved on: 
Wednesday, October 18, 2023
ASX, Survival, Pancreatic cancer, Ageing, Cancer, Health, Mortality, UK Biobank, Genetypes, Risk, GTG, Patient, Pharmaceutical industry, Medical imaging

GeneType’s Pancreatic Cancer risk assessment test showed a nearly 50% improvement to the traditional clinical risk score in identifying patients at a high risk of developing pancreatic cancer.

Key Points: 
  • GeneType’s Pancreatic Cancer risk assessment test showed a nearly 50% improvement to the traditional clinical risk score in identifying patients at a high risk of developing pancreatic cancer.
  • GeneType for Pancreatic Cancer will lead to a significant improvement to the number of pancreatic cancers being discovered earlier.
  • Pancreatic cancer has the poorest 5-year survival rate of any major solid tumour, but when diagnosed at an early stage, survival rates improve.
  • Implementing geneType risk assessment test for pancreatic cancer will help doctors diagnose the disease earlier, intervene earlier and reduce this appalling mortality.

GTG Signs Precision Medicine Pilot with Australia’s Largest Private Hospital Network

Retrieved on: 
Wednesday, September 27, 2023
Gold Coast Private Hospital, US Foods, Partnership, Surgeon, Gold Coast, Workflow, GTG, Personalized medicine, ASX, Hospital, Patient, Gold, Genetypes, Medicine, Multi, Research, Health, FDA, Food, Pharmaceutical industry, Medical imaging, Pharmacogenomics, Healthscope

Pilot study will utilise geneType Multi-risk test combined with Pharmacogenomics (PGx) tests, providing a comprehensive wellness profile for GCPH patients.

Key Points: 
  • Pilot study will utilise geneType Multi-risk test combined with Pharmacogenomics (PGx) tests, providing a comprehensive wellness profile for GCPH patients.
  • Positive outcomes could enable the rollout of additional Precision Medicine Clinics throughout the Healthscope network.
  • Gold Coast Private Hospital by Healthscope is a 336 bed, 22 theatre hospital and home to leading doctors and surgeons from around the world.
  • Healthscope is Australia's only national private hospital operation and healthcare provider with a network of 42 hospitals that service every state and territory with 19,000 employees.

GENE Positioned at the Forefront of Multi-cancer Clinical Utility Research - MRFF Grant names GTG as sole Industry Partner

Retrieved on: 
Monday, September 11, 2023
Cancer, MRFF, University, Royal Melbourne Hospital, Cancer Australia, Bureau of Oceans and International Environmental and Scientific Affairs, National Guideline Clearinghouse, GTG, The Royal Marsden NHS Foundation Trust, Risk, University of Melbourne, Policy, ASX, Breast, Research, Genomics, Prostate, History, Queen Mary University of London, General practice, Standard of care, Melanoma, Genetypes, Scores, Biostatistics, Health, Medical Research Future Fund, Primary care, Pharmaceutical industry, Vaccine

The grant will provide funding for the CASSOWARY Trial: a randomised controlled trial of the clinical utility and cost-effectiveness of a multi-cancer polygenic risk score in general practice.

Key Points: 
  • The grant will provide funding for the CASSOWARY Trial: a randomised controlled trial of the clinical utility and cost-effectiveness of a multi-cancer polygenic risk score in general practice.
  • GTG is the National Research Partner for trial which is to be led by Professor Jon Emery.
  • The trial results will inform future policy including the 5-year goal in the Australian Cancer Plan of using genomics for risk-stratified cancer screening.
  • As the sole industry partner, GTG will receive funding to cover the supply of test kits and the analysis of the sample returned.

Annual Results – Momentum Building on our Commercial Plans

Retrieved on: 
Wednesday, August 30, 2023
Momentum, Pancreatic cancer, DTC, DSM-IV codes, Partnership, QIAGEN, Health, GTG, Atrial fibrillation, Internet, Woman, ASX, Medicine, Science, Trust, Publication, Guideline, Patient, Risk, Melanoma, Genetypes, Cancer, National Farm Medicine Center, Affinity, Applied Genetic Technologies Corporation, Genetic testing, BRCA, Research, Breast cancer, Empowerment, Breast, Automation, Tourism, Medical device, Pharmaceutical industry, Growth

Our commitment to transforming healthcare through personalized genetic insights continues driving meaningful advancements, revolutionizing medical practices across the globe.

Key Points: 
  • Our commitment to transforming healthcare through personalized genetic insights continues driving meaningful advancements, revolutionizing medical practices across the globe.
  • Highlighting our commercial progress, the company announces revenues for the 12 months ending June 30, 2023, of A$8.686million, an increase of +A$1.891m; +28% compared with 2022.
  • Momentum building - Growth and Partnerships:
    The dedication of our team, and the power of geneType, have ignited a revolution in healthcare.
  • We are seeing encouraging growth in our commercial volumes for geneType, a testament to the value and trust we are building in the medical community.

Quarterly Activities Update: Encouraging Growth for geneType Commercial Test Volume

Retrieved on: 
Friday, July 28, 2023
Pancreatic cancer, BIO, UK Biobank, Medical Affairs Bureau, Partnership, Prostate cancer, GTG, Single-nucleotide polymorphism, PRS, NATA, Cancer, Risk assessment, MSL, Prostate, Medical science liaison, Publication, ASCO, Genetypes, CLIA, Traction, Patient, Risk, 40th National Television Festival, Growth, Diagnosis, Mortality, R, Health, Society, Disease, Tourism, Pharmaceutical industry, Dairy, Vaccine, Medical imaging, Melanoma

GeneType Multi-risk test gaining traction with 250% growth in commercial samples received compared with the prior quarter off a low initial base.

Key Points: 
  • GeneType Multi-risk test gaining traction with 250% growth in commercial samples received compared with the prior quarter off a low initial base.
  • 20 Medical practices in the U.S. and Australia now repeatedly referring samples for geneType testing – adding new practices incrementally every week.
  • Growth in the commercial traction of the company’s geneType brand was experienced in both Australia and the U.S.
  • Implementing geneType risk assessment test for pancreatic cancer will help doctors diagnose the disease and intervene earlier, reducing this appalling mortality.

GeneType featured on U.S. National TV to raise Breast Cancer Awareness

Retrieved on: 
Tuesday, May 23, 2023
GTG, Breast cancer, Woman, ASX, Genetypes, Marker beacon, Risk, Health, Balancing Act, Disease, Birth control

In the segment Dr. Carolynn Young and Dr. Joel Evans discuss factors that influence breast cancer risk and the clinical utility of geneType for Breast Cancer.

Key Points: 
  • In the segment Dr. Carolynn Young and Dr. Joel Evans discuss factors that influence breast cancer risk and the clinical utility of geneType for Breast Cancer.
  • Dr. Carolynn Young promotes our geneType test for Breast Cancer as a great tool for women wanting to know and reduce their risk of developing breast cancer.
  • Dr. Evans commented that he believes “the best way to look at breast cancer risk is through the geneType collection kit.” GeneType for Breast Cancer integrates over 300 genetic markers for breast cancer as well as clinical and familial factors to give a comprehensive and individualized risk prediction score.
  • Find out your underlying genetic risk of developing breast cancer with geneType - so that you and your doctor can have proactive discussions about your health, which could include adapting your screening intervals and types, and making lifestyle modifications to reduce your risk of breast cancer.

New Publication Validates geneType for Melanoma Risk Assessment

Retrieved on: 
Friday, April 28, 2023
Medical Affairs Bureau, GTG, PRS, Skin cancer, Risk management, Risk assessment, ASX, Research, Melanoma, Patient, Risk, Genetypes, Cancer, Western world, Diagnosis, Health, Melanoma Research, Medical device, Vaccine, Medical imaging

Identified the top 20% of people who were at 2.3 times increased risk of melanoma compared to the population average by combining the PRS and a clinical risk score to predict 10-year risk of melanoma.

Key Points: 
  • Identified the top 20% of people who were at 2.3 times increased risk of melanoma compared to the population average by combining the PRS and a clinical risk score to predict 10-year risk of melanoma.
  • The publication – the 6th publication in the last 5 months – highlights GTG’s commitment to ongoing scientific development of the geneType suite of risk assessment tests.
  • The paper entitled “ Melanoma risk prediction based on a polygenic risk score and clinical risk factors ” was published in the peer-reviewed journal Melanoma Research.
  • The study demonstrated that the geneType risk assessment test for Melanoma offered a significant improvement in risk assessment compared with the clinical model alone in assessing a person’s risk of melanoma.

Quarterly Business Update – March 2023

Retrieved on: 
Thursday, April 27, 2023
KOL, DSM-IV codes, QIAGEN, Partnership, Atrial fibrillation, Q&A, GTG, Marketing, BIM, CIT, ADS, Cardiovascular disease, Pancreatic cancer, American depositary receipt, ASX, MSL, Medical science liaison, Sale, Genetypes, Publication, Poster, Patient, Cancer, Medicine, Consumer, CFO, Growth, BRCA, Health, Ovarian cancer, Breast cancer, Society, Automation, Prostate cancer, Commercial property, Pharmaceutical industry, Melanoma, Breast

MELBOURNE, Australia, April 27, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, ”Company”, “GTG”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, releases its Appendix 4C and Quarterly business update for the quarter ending 31 March 2023 (Q3 FY23).

Key Points: 
  • MELBOURNE, Australia, April 27, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, ”Company”, “GTG”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, releases its Appendix 4C and Quarterly business update for the quarter ending 31 March 2023 (Q3 FY23).
  • Commenting on the Company’s quarterly performance, Chief Executive Officer Simon Morriss said: “I am pleased to report that we continue to see strong momentum across our business.
  • Our Budget Impact Model (BIM) is a core initiative underpinning the company’s Business to Business strategy.
  • GTG’s CEO, Simon Morriss, and CFO & Company Secretary, Tony Di Pietro will host an investor webinar, to discuss the March 2023 Quarterly Activities Report and hold a Q&A session.

Publication Validates geneType Prostate Cancer Risk Test

Retrieved on: 
Wednesday, April 19, 2023
UK Biobank, Medical Affairs Bureau, Prostate cancer, GTG, Cardiovascular disease, Risk assessment, ASX, Research, Prostate, Patient, Risk, Genetypes, Prostate-specific antigen, Diagnosis, Health, Ovarian cancer, PSA, Breast cancer, Vaccine, Dairy, Medical device, Medical imaging

geneType Prostate Cancer Risk Assessment Test was able to identify 23% more men at high risk of developing prostate cancer than family history alone.

Key Points: 
  • geneType Prostate Cancer Risk Assessment Test was able to identify 23% more men at high risk of developing prostate cancer than family history alone.
  • The publication highlights GTG’s commitment to ongoing scientific development of the geneType suite of risk assessment tests – being the 5th publication in the last 6 months – covering ovarian cancer, cardiovascular disease & type 2 diabetes, breast cancer (2) and prostate cancer.
  • The study demonstrated that geneType Prostate Cancer Risk Assessment Test offered a significant improvement in risk assessment when compared with age and family history in assessing a man’s risk of developing prostate cancer.
  • Importantly, geneType was we also able to identify men at very low risk of developing prostate cancer.

GeneType Multi-Risk Test now includes Melanoma, Pancreatic Cancer & Atrial Fibrillation

Retrieved on: 
Monday, March 27, 2023
Pancreatic cancer, DSM-IV codes, Atrial fibrillation, Centers for Disease Control and Prevention timeline, GTG, Woman, ASX, Life expectancy, CDC, Death, Genetypes, Patient, Risk, Melanoma, Cancer, Disease, Diagnosis, Mortality, American Cancer Society, Health, Pharmaceutical industry, Dietary supplement, Ventricular fibrillation

This launch is in line with phase 2 rollout plan for the geneType Multi Risk-Test.

Key Points: 
  • This launch is in line with phase 2 rollout plan for the geneType Multi Risk-Test.
  • The expanded panel now includes:
    Melanoma, Pancreatic Cancer and Atrial Fibrillation - broadening of the utility to 9 serious diseases.
  • Each of the three new diseases that have been added to GeneType Multi-Test cause significant mortality and morbidity.
  • The Society’s estimates for pancreatic cancer are even more dramatic with 64,050 people newly diagnosed in 2023, with a staggering 50,550 people expected to die.